Organon & Co (OGN)
20.66
-0.02
(-0.10%)
USD |
NYSE |
May 07, 13:55
Organon Enterprise Value: 13.46B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 13.46B |
| May 03, 2024 | 13.18B |
| May 02, 2024 | 13.15B |
| May 01, 2024 | 12.98B |
| April 30, 2024 | 12.92B |
| April 29, 2024 | 13.00B |
| April 26, 2024 | 12.91B |
| April 25, 2024 | 12.88B |
| April 24, 2024 | 12.95B |
| April 23, 2024 | 12.90B |
| April 22, 2024 | 12.77B |
| April 19, 2024 | 12.72B |
| April 18, 2024 | 12.73B |
| April 17, 2024 | 12.73B |
| April 16, 2024 | 12.71B |
| April 15, 2024 | 12.69B |
| April 12, 2024 | 12.63B |
| April 11, 2024 | 12.84B |
| April 10, 2024 | 12.81B |
| April 09, 2024 | 12.87B |
| April 08, 2024 | 12.81B |
| April 05, 2024 | 12.71B |
| April 04, 2024 | 12.71B |
| April 03, 2024 | 12.72B |
| April 02, 2024 | 12.78B |
| Date | Value |
|---|---|
| April 01, 2024 | 12.87B |
| March 31, 2024 | 12.95B |
| March 28, 2024 | 12.87B |
| March 27, 2024 | 12.78B |
| March 26, 2024 | 12.70B |
| March 25, 2024 | 12.62B |
| March 22, 2024 | 12.61B |
| March 21, 2024 | 12.75B |
| March 20, 2024 | 12.71B |
| March 19, 2024 | 12.65B |
| March 18, 2024 | 12.62B |
| March 15, 2024 | 12.74B |
| March 14, 2024 | 12.76B |
| March 13, 2024 | 12.81B |
| March 12, 2024 | 12.74B |
| March 11, 2024 | 12.76B |
| March 08, 2024 | 12.78B |
| March 07, 2024 | 12.73B |
| March 06, 2024 | 12.66B |
| March 05, 2024 | 12.60B |
| March 04, 2024 | 12.51B |
| March 01, 2024 | 12.56B |
| February 29, 2024 | 12.52B |
| February 28, 2024 | 12.63B |
| February 27, 2024 | 12.68B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.592B
Minimum
Jun 09 2021
18.38B
Maximum
Mar 02 2022
14.71B
Average
14.74B
Median
Sep 26 2022
Enterprise Value Benchmarks
| Amgen Inc | 215.00B |
| Merck & Co Inc | 351.77B |
| Pfizer Inc | 217.89B |
| Alnylam Pharmaceuticals Inc | 17.78B |
| Moderna Inc | 38.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 201.00M |
| Revenue (Quarterly) | 1.622B |
| Total Expenses (Quarterly) | 1.208B |
| EPS Diluted (Quarterly) | 0.78 |
| Gross Profit Margin (Quarterly) | 59.00% |
| Profit Margin (Quarterly) | 12.39% |
| Earnings Yield | 19.80% |
| Operating Earnings Yield | 25.39% |
| Normalized Earnings Yield | 21.85 |